Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Savient Nuflexxa Approval For Knee Arthritis May Aid Sale Of BTG Unit

This article was originally published in The Gray Sheet

Executive Summary

Savient Pharmaceuticals' planned divestiture of its Bio-Technology General unit to fund drug R&D could get a boost from PMA approval of its hyaluronic acid injection for knee osteoarthritis, announced Dec. 7

You may also be interested in...

Osteoarthritis Knee-Treatment Device Firms Clash Over Physician Fees

Genzyme is urging CMS to retain a single HCPCS procedure billing code for the three hyaluronic acid-based devices competing with its Synvisc

Basilea Stresses Derazantinib's FGFR Kinase Differentiation

Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts